Determinants of long-term survival in patients with IDH-mutant gliomas
Journal of Neuro-Oncology · 2024
DOI: 10.1007/s11060-024-04826-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Sophie Katzendobler und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Brain Neoplasms, Glioma, Mutation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Klinikum der Universität München.
Abstract (Originalsprache)
Background
Survival times of patients with IDH-mutant gliomas are variable and can extend to decades. Many studies provide progression-free rather than overall survival times and prognostic factors remain ill-defined. Here we explored characteristics of short- and long-term survivors within a cohort of patients with extended follow-up.
Methods
This single-center, case-control study included 86 patients diagnosed between 1998 and 2023 who either died within 6 years after diagnosis or survived at least 15 years. Patient characteristics and prognostic factors were stratified by short- (< 6 years) versus long-term (≥ 15 years) survival.
Results
Forty-seven patients (55%) diagnosed with astrocytoma and 39 patients (45%) with oligodendroglioma were included retrospectively. Median follow-up of the survivors was 16.6 years (range 15-28.9). Thirty-four deaths (40%) had been reported at database closure. Long-term survival was associated with CNS WHO grade 2 ( p < 0.01), smaller tumor volumes ( p = 0.01), lack of contrast enhancement ( p < 0.01), wait-and-scan strategies ( p < 0.01) and female sex ( p = 0.04). In multivariate analyses for oligodendroglioma, larger T2 tumor volumes were associated with shorter survival (HR 1.02; 95% CI 1.01–1.05; p = 0.04). In patients with astrocytoma, lack of contrast enhancement (HR 0.38; 95% CI 0.15–0.94; p = 0.04) and wait-and-scan strategies (HR 5.75; 95% CI 1.66–26.61; p = 0.01) were associated with longer survival.
Conclusion
Large T2 tumor volume and contrast enhancement may be important risk factors for shorter survival, while age might be of lesser importance. Wait-and-scan strategies may yield excellent long-term survival in some patients with astrocytoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
- Department of Neuroradiology, LMU University Hospital, LMU Munich, Germany.
- Center for Neuropathology and Prion Research, LMU University Hospital, LMU Munich, Munich, Germany.
- German Consortium for Translational Cancer Research (DKTK), Partner Site Munich, Heidelberg, Germany.
- Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
- Department of Neurosurgery, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany. jonathan.weller@med.uni-muenchen.de.
Förderung
- Klinikum der Universität München
Zitieren
APA
Katzendobler, S., Niedermeyer, S., Blobner, J., Trumm, C., Harter, P. N., von Baumgarten, L., Stoecklein, V. M., Tonn, J. C., Weller, M., Thon, N., & Weller, J. (2024). Determinants of long-term survival in patients with IDH-mutant gliomas. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04826-9
Vancouver
Katzendobler S, Niedermeyer S, Blobner J, Trumm C, Harter PN, von Baumgarten L, et al. Determinants of long-term survival in patients with IDH-mutant gliomas. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04826-9
BibTeX
@article{Katzendobler2024,
author = {Katzendobler, Sophie and Niedermeyer, Sebastian and Blobner, Jens and Trumm, Christoph and Harter, Patrick N and von Baumgarten, Louisa and Stoecklein, Veit M and Tonn, Joerg-Christian and Weller, Michael and Thon, Niklas and Weller, Jonathan},
title = {Determinants of long-term survival in patients with IDH-mutant gliomas},
journal = {Journal of Neuro-Oncology},
year = {2024},
doi = {10.1007/s11060-024-04826-9}
}
EUVIMED